Unknown

Dataset Information

0

CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.


ABSTRACT: BACKGROUND:Locally advanced nasopharyngeal carcinoma (LA-NPC) is a relatively rare disease in the west but more common in East Asia and areas of the Middle East like Saudi Arabia. Despite the advances in radiation therapy techniques, some patients relapse after treatment. In the coming era of cancer immunotherapy, prognostic factors for LA-NPC need to be further defined using immune-relevant markers. Several markers are available; however, the most robust and accessible/affordable marker is not well-defined. METHODS:Retrospectively, tumor-infiltrating lymphocytes (TIL), their subsets as well as tumoral PD-L1 expression were analyzed in tumor tissues from 63 LA-NPC patients treated with platinum-based concurrent chemo-radiotherapy (CCRT) in addition to 20 cases with metastatic (MET) disease. Immunostaining was done using a validated and fully automated system. Scoring was done by two independent pathologists and results were compared. RESULTS:There was no statistical difference between LA-NPC and MET disease in terms of CD3+, CD8+ TIL infiltration, or tumoral PD-L1 expression. In LA-NPC, low CD3+ TIL infiltration highly correlated with shorter disease-free survival (DFS, HR?=?8.5, p?=?

SUBMITTER: Al-Rajhi N 

PROVIDER: S-EPMC7227256 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.

Al-Rajhi Nasser N   Soudy Hussein H   Ahmed Shoaib A SA   Elhassan Tusneem T   Mohammed Shamayel F SF   Khoja Hatim A HA   Ghebeh Hazem H  

BMC cancer 20200321 1


<h4>Background</h4>Locally advanced nasopharyngeal carcinoma (LA-NPC) is a relatively rare disease in the west but more common in East Asia and areas of the Middle East like Saudi Arabia. Despite the advances in radiation therapy techniques, some patients relapse after treatment. In the coming era of cancer immunotherapy, prognostic factors for LA-NPC need to be further defined using immune-relevant markers. Several markers are available; however, the most robust and accessible/affordable marker  ...[more]

Similar Datasets

| S-EPMC8601301 | biostudies-literature
| S-EPMC6036165 | biostudies-other
| S-EPMC7893927 | biostudies-literature
| S-EPMC8804347 | biostudies-literature
| S-EPMC9241295 | biostudies-literature
| S-EPMC5513538 | biostudies-literature
| S-EPMC3446382 | biostudies-literature
| S-EPMC6525458 | biostudies-literature
| S-EPMC7154488 | biostudies-literature
| S-EPMC8096375 | biostudies-literature